Prevention and treatment of thromboembolic disorders

US9539218B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Frank Misselwitz · Heidelberg, DE
• Dagmar Kubitza · Ratingen, DE
• Son-Mi Park · Wuppertal, DE
• Klaus Wehling · Wuppertal, DE

Key dates

• Filing date: Jan 19, 2006
• Grant date: Jan 10, 2017
• Expiry date: Feb 17, 2034

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P9/10
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to the field of blood coagulation, more specifically it relates to a method of treating a thromboembolic disorder by administering once daily a direct factor Xa inhibitor in oral dosage form to a patient in need thereof, wherein the factor Xa inhibitor has a plasma concentration half life indicative of a bid or tid administration interval, e.g. of 10 hours or less.